Oncology

As president and CEO of Cancer Treatment Centers of America, Pat A. Basu, MD, MBA, looks to transform, improve, and influence cancer care on a large scale.

CMS won't require on-site supervision by oncologists at hospital outpatient departments

FDA cleared the first generic sodium iodide product to treat hyperthyroidism and carcinoma of the thyroid.

Breakthrough treatments for lung cancer and melanoma have driven down cancer deaths, seeing the largest ever decline from 2016 to 2017. 

How a joint accountability arrangement between Minnesota Blues and Minnesota Oncology hopes to lower patient costs and improve outcomes.

Collaboration within the healthcare industry is needed to push the cancer death rate down.

Cancer treatment is becoming more personalized. Here’s how.

Oncological facilities that promote flexibility are the ones best suited to care for the needs of their patient population.

Because the disease in males is rare, they have historically been excluded from clinical trials of breast cancer drugs.

FDA is evaluating risks to patients.

From breast cancer to prostate cancer, the state of oncology care and how it will evolve.

FDA approved yet another indication for pembrolizumab (Keytruda) to treat patients with recurrent, locally advanced or metastatic, squamous cell carcinoma of the esophagus (ESCC).

Customized survivorship plans specific to the cancer the patient endured and the treatment they received are essential.

Oncologists are under intense pressure to come up with cost savings-and many are turning to value-based care structures.

Top oncology experts share how they deliver these therapies to patients in need.

A record number of new oncology treatments launched in the US last year and spending on cancer drugs soared. Here are the top 6 cancer drug trends revealed in the report.

A new NIH report on cancer in people aged 20 to 49 shows that while rates are declining, women and minorities still face significant rates.

Oncologists recognize the potential of artificial intelligence (AI) in improving the quality of care and patient outcomes according to new research.

The 2018 oncology drug market had a record number of new treatments and continued a trend of growth.

Biosimilar drugs are poised to transform the cancer drug market-so why is uptake so slow?

Managed Healthcare Executive asked top experts their predictions for the top game-changing therapies. Here’s what they said.

Jim Barlow of Geneos Therapeutics explains the role of value networks and strategies to increase cell therapy access.

FDA approves cabozantinib to treat patients with hepatocellular carcinoma, a community in need of new therapeutic options.

How Horizon BCBSNJ’s Episodes of Care program engages physicians in certain specialties in the value-based continuum.

IO therapies hold great promise, but often come with high price tags. How do payers feel about these medications?